How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?
ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.
Open original sourceLoading market dashboard
ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.
Open original source